Resurrect Bio, a London-based agricultural biotechnology company, has closed an oversubscribed Series A funding round totaling €8.8 million ($10.3 million), with Corteva serving as the lead investor through its Corteva Catalyst platform.
The funding represents a significant milestone for the UK-based startup, which had already achieved an initial close of over €6.8 million in February 2026. The oversubscribed nature of the round underscores investor confidence in the company’s mission to develop disease-resistant crop varieties that address pressing challenges in global agriculture.
Accelerating Crop Disease Solutions
The capital injection will enable Resurrect Bio to advance its core focus: developing crops with enhanced resistance to diseases that threaten agricultural productivity worldwide. As food security concerns intensify across Europe and globally, solutions that can protect yields without increasing chemical inputs have attracted growing attention from both agribusiness corporations and venture investors.
Corteva, one of the world’s largest agricultural input companies, brings not only financial resources but also substantial industry expertise and market access to the partnership. Through its Corteva Catalyst investment platform, the company has positioned itself as a strategic backer of innovative agritech ventures that align with its broader sustainability and productivity objectives.
Timing and Market Context
The completion of Resurrect Bio’s Series A round comes amid heightened focus on agricultural innovation across Europe. Regulatory pressures, climate variability, and evolving pest and disease pressures have created compelling commercial opportunities for biotechnology solutions that can enhance crop resilience. The UK startup’s focus on disease resistance addresses one of agriculture’s most persistent challenges, where crop losses to pathogens continue to threaten farmer profitability and food availability.
The oversubscribed outcome suggests that multiple investors saw merit in Resurrect Bio’s approach, even as the company already had substantial backing from its initial February close. This investor enthusiasm reflects broader market recognition that agricultural biotechnology represents a critical area for innovation and investment.
European AgriTech Innovation
Resurrect Bio’s fundraising success adds to a growing body of evidence that European agritech startups are attracting significant capital and corporate backing. The UK, despite post-Brexit considerations, remains a hub for agricultural innovation, with London serving as a nexus for agritech venture activity alongside other European innovation centers. Corporate venture participation from established players like Corteva has become increasingly common, as major agricultural companies recognize that breakthrough technologies often emerge from nimble startup operations rather than traditional R&D departments.
The company’s progression from initial close to full Series A completion demonstrates the maturation of deal structures in the agritech space, where lead investors may structure funding rounds across multiple tranches while maintaining momentum and investor engagement throughout the process.